CA2506290C - 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases - Google Patents

17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases Download PDF

Info

Publication number
CA2506290C
CA2506290C CA2506290A CA2506290A CA2506290C CA 2506290 C CA2506290 C CA 2506290C CA 2506290 A CA2506290 A CA 2506290A CA 2506290 A CA2506290 A CA 2506290A CA 2506290 C CA2506290 C CA 2506290C
Authority
CA
Canada
Prior art keywords
compound
isomer
pharmaceutically acceptable
solvate
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2506290A
Other languages
English (en)
French (fr)
Other versions
CA2506290A1 (en
Inventor
Kamil Paruch
Timothy J. Guzi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CA2506290A1 publication Critical patent/CA2506290A1/en
Application granted granted Critical
Publication of CA2506290C publication Critical patent/CA2506290C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
CA2506290A 2002-11-18 2003-11-14 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases Expired - Fee Related CA2506290C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42726302P 2002-11-18 2002-11-18
US60/427,263 2002-11-18
PCT/US2003/036203 WO2004046111A1 (en) 2002-11-18 2003-11-14 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases

Publications (2)

Publication Number Publication Date
CA2506290A1 CA2506290A1 (en) 2004-06-03
CA2506290C true CA2506290C (en) 2012-04-24

Family

ID=32326512

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2506290A Expired - Fee Related CA2506290C (en) 2002-11-18 2003-11-14 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases

Country Status (16)

Country Link
US (2) US7074795B2 (enExample)
EP (1) EP1562901B1 (enExample)
JP (2) JP4614770B2 (enExample)
CN (1) CN100374421C (enExample)
AR (1) AR042046A1 (enExample)
AT (1) ATE469886T1 (enExample)
AU (1) AU2003290799A1 (enExample)
CA (1) CA2506290C (enExample)
CL (1) CL2003002356A1 (enExample)
DE (1) DE60332862D1 (enExample)
ES (1) ES2345146T3 (enExample)
MX (1) MXPA05005360A (enExample)
MY (1) MY130792A (enExample)
PE (1) PE20040750A1 (enExample)
TW (1) TW200412964A (enExample)
WO (1) WO2004046111A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053091B2 (en) 2002-12-17 2006-05-30 Schering Corporation 17 β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
GB0513702D0 (en) 2005-07-04 2005-08-10 Sterix Ltd Compound
WO2007016496A2 (en) * 2005-08-02 2007-02-08 Neurogen Corporation Dipiperazinyl ketones and related analogues
US8080540B2 (en) 2006-09-19 2011-12-20 Abbott Products Gmbh Therapeutically active triazoles and their use
US8288367B2 (en) 2006-11-30 2012-10-16 Solvay Pharmaceuticals Gmbh Substituted estratriene derivatives as 17BETA HSD inhibitors
US8501940B2 (en) * 2008-07-15 2013-08-06 Hoffmann-La Roche Inc. Tetrahydrocinnoline derivatives
JP5934781B2 (ja) * 2011-04-25 2016-06-15 パーク、ジュン−ヒョン 脱毛防止及び発毛促進用外用剤組成物
CN105518015B (zh) 2013-06-25 2017-09-15 佛恩多制药有限公司 治疗活性的作为17β‑羟基类固醇脱氢酶抑制剂的17‑氮取代雌三烯噻唑衍生物
EP3013845B1 (en) 2013-06-25 2020-03-18 Forendo Pharma Ltd Therapeutically active estratrienthiazole derivatives as inhibitors of 17b-hydroxysteroid dehydrogenase, type 1
US9850272B2 (en) 2013-06-25 2017-12-26 Forendo Pharma Ltd. Therapeutically active estratrienthiazole derivatives as inhibitors of 17.beta-hydroxy-steroid dehydrogenase, type 1
WO2016102775A1 (en) 2014-12-23 2016-06-30 Forendo Pharma Ltd PRODRUGS OF 17β-HSD1 -INHIBITORS
WO2016102776A1 (en) 2014-12-23 2016-06-30 Forendo Pharma Ltd Prodrugs of 17.beta.-hsd1 -inhibitors
CN108137542B (zh) 2015-09-02 2023-10-27 葛兰素史克知识产权第二有限公司 用作溴结构域抑制剂的吡啶酮二甲酰胺
NZ760155A (en) 2017-06-08 2022-09-30 Forendo Pharma Ltd 15.beta.-[3-propanamido]-substituted estra-1,3,5
SG11202005365WA (en) 2017-12-15 2020-07-29 Inthera Bioscience AG 1 -(piperidinocarbonylmethyl)-2-oxopiperazine derivatives for treating cancer
KR20210114390A (ko) 2018-12-05 2021-09-23 포렌도 파마 리미티드 17-hsd1의 억제제로서의 피라졸 고리와 위치 16(17)에서 축합된 에스트라-1,3,5(10)-트리엔 화합물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0195015B1 (en) 1984-08-02 1992-05-13 LABRIE, Fernand Pharmaceutical composition for combination therapy of hormone dependent cancers
AU5281990A (en) 1989-03-10 1990-10-09 Endorecherche Inc. Combination therapy for treatment of estrogen sensitive diseases
EP0595796B1 (en) 1989-07-07 2003-01-15 Endorecherche Inc. Method of treatment of androgen-related diseases
DK0943328T3 (da) 1989-07-07 2004-10-18 Endorech Inc Kombinationsterapi til profylakse og/eller behandling af godartet prostatahyperplasi
US6060503A (en) 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
DE69329649D1 (de) 1993-05-17 2000-12-14 Endorech Inc Verbesserte antiandrogene
US6124115A (en) 1995-09-22 2000-09-26 Endorecherche Inc. Production and use of isolated type 5 17β-hydroxysteroid dehydrogenase
AU4801197A (en) * 1996-09-13 1998-04-02 Schering Corporation Tricyclic antitumor compounds being farnesyl protein transferase inhibit ors
RU2000125533A (ru) 1998-03-11 2002-10-20 Эндорешерш, Инк. (Ca) Ингибиторы 17-бета-гидроксистероиддегидрогеназ 5 и 3 типа и способы их применения
AR036492A1 (es) * 2001-09-06 2004-09-15 Schering Corp Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3, composiciones farmaceuticas y el uso de dichos inhibidores para la elaboracion de un medicamento para el tratamiento de enfermedades androgeno dependientes
PE20030705A1 (es) 2001-10-17 2003-08-21 Schering Corp Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes

Also Published As

Publication number Publication date
US20040127503A1 (en) 2004-07-01
AR042046A1 (es) 2005-06-08
US7074795B2 (en) 2006-07-11
CN1738800A (zh) 2006-02-22
DE60332862D1 (de) 2010-07-15
HK1073313A1 (en) 2005-09-30
MXPA05005360A (es) 2005-08-03
JP2006513169A (ja) 2006-04-20
ATE469886T1 (de) 2010-06-15
WO2004046111A1 (en) 2004-06-03
EP1562901B1 (en) 2010-06-02
PE20040750A1 (es) 2004-11-06
ES2345146T3 (es) 2010-09-16
US7476681B2 (en) 2009-01-13
CL2003002356A1 (es) 2005-02-11
JP4614770B2 (ja) 2011-01-19
EP1562901A1 (en) 2005-08-17
US20060148816A1 (en) 2006-07-06
MY130792A (en) 2007-07-31
CA2506290A1 (en) 2004-06-03
JP2010138204A (ja) 2010-06-24
AU2003290799A1 (en) 2004-06-15
TW200412964A (en) 2004-08-01
CN100374421C (zh) 2008-03-12

Similar Documents

Publication Publication Date Title
CA2506290C (en) 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
JP2006514054A5 (enExample)
US6767926B1 (en) Method for protecting normal cells from cytotoxicity of chemotherapeutic agents
WO2003080580A3 (en) Quinoline derivatives and their use as 5-ht6 ligands
PL357574A1 (en) Antitumoral ecteinascidin derivatives
HK1048298A1 (zh) 比卡鲁胺(casodex)及其衍生物以及其中间产物的对映体的不对称合成法
GB0117583D0 (en) Novel compounds
DE60132606D1 (de) Isochinolinone als kalium-kanal-inhibitoren
JP2006513169A5 (enExample)
CA2463505A1 (en) Low-calcemic oxime analogs of 1.alpha.,25-dihydroxy vitamin d3
MXPA04000411A (es) Tiazolidinonas arilo sustituidas y uso de las mismas.
IS7118A (is) Þíenópýrimidíndíón og notkun þeirra í breytingu ásjálfnæmissjúkdómum
UY28877A1 (es) Compuestos de metil-aril o heteroaril-amida sustituida y composiciones
MA29239B1 (fr) Derives de n- (heteroaryl) -1h-ind0le-2-carb0xamids et leur utilisation comme ligands du recepteur vanilloide trpv1
WO2004084812A3 (en) Tamandarin analogs and fragments thereof and methods of making and using
CR20220478A (es) Derivados de benzodiazepinas como pam de gaba a gamma 1
UA86013C2 (ru) Производные арилалкилкарбаматов, их получение и применение в лечении
TW200612920A (en) Novel imidazolidine derivatives
PL362766A1 (en) Novel imidazole derivatives, production method thereof and use thereof
ATE381554T1 (de) Aroylfurane und aroylthiophene, die sich für die behandlung von krebs eignen
AU780844B2 (en) Method for protecting normal cells from cytotoxicity of chemotherapeutic agents
EA200100090A2 (ru) Новые пиперидин-4-сульфонамидные производные, способ их получения и содержащие их фармацевтические композиции
EA200601106A1 (ru) Трициклические имидазопиридины для применения в качестве ингибиторов желудочной секреции
EA200000929A3 (ru) Новые цианоиндольные соединения-ингибиторы повторного захвата серотонина, способ их получения и содержащие их фармацевтические композиции
DK1161424T3 (da) Hidtil ukendte diazolderivater som serotonerge midler

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20141114